BioElectronics To Announce Results Of Acetaminophen Comparison Study

Main Category: Pain / Anesthetics
Article Date: 12 Nov 2009 - 3:00 PDT

email to a friend   printer friendly   opinions  

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that results from the recently completed acetaminophen comparison study will be released on Monday, November 16th after the close of the market. The study compares the effects of ActiPatch® Therapy to acetaminophen in the form of Extra Strength Tylenol® for the treatment of Delayed Onset Muscle Soreness (DOMS).

Participants in the study were randomly assigned to one of three groups, 1) a control group, 2) a group that used ActiPatch, and 3) a group that was treated with over-the-counter strength acetaminophen in the form of Extra Strength Tylenol. Each of the group's participants then evaluated their levels of muscle soreness and discomfort 48 hours after vigorous resistance training designed to induce delayed onset muscle soreness.

"The results for the pilot section of this study were highly significant with the ActiPatch group scoring its average level of muscle soreness and discomfort at much lower levels compared to either the control group or the acetaminophen treatment group," commented Andrew Whelan, CEO of BioElectronics, Corp. "We believe this is important research especially considering the many health concerns expressed by the U.S. Food and Drug Administration relative to Tylenol, NSAIDs and other over the counter pain medications. We believe ActiPatch and Allay are both safe and highly effective alternative therapies for those who suffer from pain and discomfort. We look forward to reviewing the full study data and submitting it to FDA in support of our current pending 510(K) applications and additional applications we plan to file in the future."

The study, which is Institutional Review Board (IRB) supervised and has been registered with the National Institutes of Health, is being conducted by principal investigator Sheena Kong, M.D. The principal investigator holds no financial position in any form in the study's sponsor, BioElectronics Corp., and will receive no financial compensation of any kind for the completion of the study.

Source
BioElectronics Corporation

• Additional
• References
• Citations